<DOC>
	<DOCNO>NCT00082641</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . Drugs use chemotherapy , doxorubicin , cyclophosphamide , paclitaxel , work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Giving vaccine therapy and/or chemotherapy radiation therapy may cause strong immune response . PURPOSE : This randomized phase I/II trial study side effect two regimen vaccine therapy see well work treat woman receive neoadjuvant adjuvant chemotherapy adjuvant radiation therapy stage III breast cancer overexpresses p53 .</brief_summary>
	<brief_title>Vaccine Therapy With Either Neoadjuvant Adjuvant Chemotherapy Adjuvant Radiation Therapy Treating Women With p53-Overexpressing Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety toxicity two different schedule vaccination comprise p53-infected autologous dendritic cell woman p53-overexpressing stage III breast cancer undergo neoadjuvant adjuvant chemotherapy adjuvant radiotherapy . - Determine immune response , term humoral cellular response , patient treat regimen . - Determine antigen-specific immune response patient treat regimen . OUTLINE : This randomize , open-label study . Patients randomize 1 2 treatment arm . All patient undergo apheresis collection peripheral blood monocyte culture interleukin-4 sargramostim ( GM-CSF ) produce dendritic cell . The dendritic cell infect recombinant adenoviral vector contain wild-type p53 gene . Patients receive doxorubicin IV cyclophosphamide IV every 2 week 8 week ( 4 course ) follow 2 week later paclitaxel IV every 2 week 8 week ( 4 course ) . Patients stage III disease undergo surgery . Three week completion paclitaxel ( surgery patient stage III disease ) , patient undergo radiotherapy daily 6.5 week . Patients receive vaccine therapy per arm randomized . - Arm I : Patients receive vaccination comprise p53-infected autologous dendritic cell subcutaneously ( SC ) 1 week completion doxorubicin cyclophosphamide , 1 week completion paclitaxel ( surgery patient stage III disease ) , 6 12 week completion radiotherapy ( total 4 vaccination ) . - Arm II : Patients receive vaccination comprise p53-infected autologous dendritic cell SC 6 , 8 , 10 , 12 week completion radiotherapy . Treatment arm continue absence unacceptable toxicity . Patients follow 1 month , every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 20-50 patient ( 10-25 per treatment arm ) accrue study within 2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive breast cancer meeting follow criterion : Clinically locally advance disease ( stage III ) primary tumor least 4 cm mammogram , ultrasound , palpation AND/OR palpable axillary node large 1 cm Planned neoadjuvant chemotherapy p53overexpressing tumor immunohistochemistry Delayedtype hypersensitivity least 1 3 standard antigen Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 19 Sex Female Menopausal status Not specify Performance status ECOG 01 Life expectancy Not specify Hematopoietic WBC &gt; 4,000/mm^3 Platelet count &gt; 100,000/mm^3 Hepatic Bilirubin &lt; 2 time upper limit normal ( ULN ) Hepatitis B surface antigen negative Hepatitis C antibody negative Renal Creatinine &lt; 2 time ULN Immunologic HIV negative No prior concurrent autoimmune disorder Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 6 month study participation No concurrent illness would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics No prior chemotherapy Endocrine therapy Not specify Radiotherapy Not specify Surgery See Disease Characteristics Other No concurrent participation another therapeutic clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>